Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab +/- Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT05420948Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, carboplatin, paclitaxel in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Chicago. Started Oct 2022; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05420948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05420948.